From multiple perspectives, it was established that anti-EPHB6 immunotherapy might be a novel therapeutic regimen for patients with BLCA, which would greatly improve the clinical outcomes of BLCA. This evidence concerns the gene EPHB6 and bladder transitional cell carcinoma.